Skip To Main Content
Xavier Charmetant on Muck Rack

Xavier Charmetant

As seen in: Wiley Online Library, Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xavier

Contact Xavier, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of Excluding Anti-HLA-C and -DP Antibodies From the Allocation System on Kidney Transplant Access

|
By Margot Lepage, Thomas Barba, Xavier Charmetant
| Wiley Online Library Verified
1 Introduction Kidney graft allocation relies on a combination of clinical, immunological, geographical, and demographic criteria, designed to balance the principles of utility and equity [1]. Among these determinants, immunological compatibility between donors and recipients plays a pivotal role, as it directly influences both graft outcomes and access to transplantation [2].
Open in Who Shared Issue with article?

Memory B Cells Provide Long‐Term Protection to Vaccinated Kidney Transplant Recipients Against SARS‐CoV‐2 Variants

|
By Maxime Espi, Xavier Charmetant, Ilies Benotmane, LabEx Transplantex
| Wiley Online Library Verified
Conflicts of Interest O.T. participated in advisory boards of Biotest, Novartis, and AstraZeneca and received research grants from Immucor, Biomerieux, and BMS. S.C. participated in advisory boards of Alexion, Hansa Pharma, and AstraZeneca and received travel grants from Sanofi, AstraZeneca, and Alexion. X.C. received speaker fees from AstraZeneca.
Open in Who Shared Issue with article?

Monitoring gait at home with radio waves in Parkinson’s disease: A marker of severity, progression, and medication response

|
By Xavier Charmetant, Jackson Liang, Armen A. Gharibans, Yingcheng Liu
| Science Magazine Verified
Gait speed as a marker of PD motor fluctuation and medication response Within 3 to 5 years of levodopa treatment, about 50% of individuals with PD begin to develop motor fluctuations (34), characterized by a decline in the duration of benefit of each dose with emergent motor fluctuations, a phenomenon known as “wearing-off” or “ON-OFF” effect (3).
Open in Who Shared Issue with article?
See all 12 articles